Ribavirin

利巴韦林

Report date: 2026/03/31 20:00:21
NME

Base Information

Drug NameRibavirin
Drug Alias NameRibavirina病毒唑Ribavirine三唑核苷Ribavirinum +[19] 
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Nucleoside analogues
Mechanisms of ActionInosine-5'-monophosphate dehydrogenase (IMPDH) inhibitorsBacterial DNA-directed RNA polymerase inhibitorsmRNA guanylyltransferase inhibitors
TargetsInosine-5'-monophosphate dehydrogenase (IMPDH)Bacterial DNA-directed RNA polymerasemRNA guanylyltransferase
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Bone marrow transplant rejectionFibrosis +[21] 
Global Approved IndicationsRespiratory Syncytial Virus InfectionsHepatitis C, ChronicHepatitis C
Approved Indications in ChinaRespiratory Syncytial Virus Infections
Original Approved Country/TerritoryMainland China
Original Approved Date1985/01/01
Country/TerritoryBulgariaCanadaUnited States +[17] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesBausch Health Companies Inc
China Registration ClassN/A

Develop Information

Active CompaniesChugai Pharmaceutical Co LtdMerck Sharp & Dohme CorpLiverpool School Of Tropical Medicine +[6] 
Inactive CompaniesSandozWeill Medical College of Cornell UniversityCairo University +[23] 
Active IndicationsCoronavirus Disease 2019 (COVID-19)Respiratory Syncytial Virus InfectionsHepatitis C +[6] 
Inactive IndicationsBone marrow transplant rejectionFibrosisAnemia, Hemolytic +[15] 

Other Information

ATC CodeJ05AP01
Related LinksWikipediaDrugBankKEGG